Selecting systemic cancer therapy one patient at a time: Is there a role for molecular profiling of individual patients with advanced solid tumors?

Journal of Clinical Oncology

Volumn 28, Issue 33, 2010, Pages 4869-4871

  Doroshow, James H ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED CANCER; BREAST CANCER; CANCER REGRESSION; CANCER SURVIVAL; CANCER THERAPY; CHRONIC MYELOID LEUKEMIA; CLINICAL EVALUATION; CLINICAL PRACTICE; COLON CANCER; COLORECTAL CANCER; DISEASE COURSE; EDITORIAL; GENE EXPRESSION PROFILING; GENE MUTATION; HUMAN; LUNG NON SMALL CELL CANCER; MEDICAL DECISION MAKING; NEEDLE BIOPSY; OVARY CANCER; PRIORITY JOURNAL; SOLID TUMOR; SYSTEMIC THERAPY; TREATMENT OUTCOME; TREATMENT RESPONSE;

CLINICAL TRIALS AS TOPIC; GENE EXPRESSION PROFILING; HUMANS; NEOPLASMS; RESEARCH DESIGN;

EID: 79951897927     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2010.31.1472     Document Type: Editorial

References (33)

1. Kessel D, Hall TC: Biochemical predictive tests, in Holland JF, Frei E III (eds): Cancer Medicine (ed 2). Philadelphia, PA, Lea & Febiger, 1982, pp 715-720
2. Burns CP, Armentrout SA, Stjernholm RL: Prediction of the response of patients with acute nonlymphocytic leukemia to cytosine arabinoside (NSC-63878) therapy. Cancer Chemother Rep 56:527-534, 1972
3. Hamburger AW, Salmon SE: Primary bioassay of human tumor stem cells. Science 197:461-463, 1977
4. Sawyers CL: The cancer biomarker problem. Nature 452:548-552, 2008
5. Tan DS, Gerlinger M, Teh BT, et al: Anti-cancer drug resistance: Understanding the mechanisms through the use of integrative genomics and functional RNA interference. Eur J Cancer 46:2166-2177, 2010
6. Dowlati A, Haaga J, Remick SC, et al: Sequential tumor biopsies in early phase clinical trials of anticancer agents for pharmacodynamic evaluation. Clin Cancer Res 7:2971-2976, 2001 (Pubitemid 32963813)
7. Kummar S, Kinders R, Gutierrez ME, et al: Phase 0 clinical trial of the poly (ADP-ribose) polymerase inhibitor ABT-888 in patients with advanced malignancies. J Clin Oncol 27:2705-2711, 2009
8. Agulnik M, Oza AM, Pond GR, et al: Impact and perceptions of mandatory tumor biopsies for correlative studies in clinical trials of novel anticancer agents. J Clin Oncol 24:4801-4807, 2006 (Pubitemid 46655611)
9. Peppercorn J, Shapira I, Collyar D, et al: Ethics of mandatory research biopsy for correlative end points within clinical trials in oncology. J Clin Oncol 28:2635-2640, 2010
10. McShane LM, Hunsberger S, Adjei AA: Effective incorporation of biomarkers into phase II trials. Clin Cancer Res 15:1898-1905, 2009
11. Dancey JE, Dobbin KK, Groshen S, et al: Guidelines for the development and incorporation of biomarker studies in early clinical trials of novel agents. Clin Cancer Res 16:1745-1755, 2010
12. Khleif SN, Doroshow JH, Hait WN: AACR-FDA-NCI Cancer Biomarkers Collaborative consensus report: Advancing the use of biomarkers in cancer drug development. Clin Cancer Res 16:3299-3318, 2010
13. Carden CP, Sarker D, Postel-Vinay S, et al: Can molecular biomarker-based patient selection in phase I trials accelerate anticancer drug development? Drug Discov Today 15:88-97, 2010
14. Freidlin B, McShane LM, Korn EL: Randomized clinical trials with biomarkers: Design issues. J Natl Cancer Inst 102:152-160, 2010
15. Sikorski R, Yao B: Parallel paths to predictive biomarkers in oncology: Uncoupling of emergent biomarker development and phase III trial execution. Sci Transl Med 1:10, 2009 (suppl 11)
16. Seymour L, Ivy SP, Sargent D, et al: The design of phase II clinical trials testing cancer therapeutics: Consensus recommendations from the clinical trial design task force of the National Cancer Institute Investigational Drug Steering Committee. Clin Cancer Res 16:1764-1769, 2010
17. Rubinstein L, Crowley J, Ivy P, et al: Randomized phase II designs. Clin Cancer Res 15:1883-1890, 2009
18. Ratain MJ: Bar the windows but open the door to randomization. J Clin Oncol 28:3104-3106, 2010
19. Ransohoff DF, Gourlay ML: Sources of bias in specimens for research about molecular markers for cancer. J Clin Oncol 28:698-704, 2010
20. Duda DG, Ancukiewicz M, Jain RK: Biomarkers of antiangiogenic therapy: How do we move from candidate biomarkers to valid biomarkers? J Clin Oncol 28:183-185, 2010
21. Sawyers CL: Even better kinase inhibitors for chronic myeloid leukemia. N Engl J Med 362:2314-2315, 2010
22. Sotiriou C, Pusztai L: Gene-expression signatures in breast cancer. N Engl J Med 360:790-800, 2009
23. Von Hoff DD, Stephenson JJ Jr, Rosen P, et al: Pilot study using molecular profiling of patients' tumors to find potential targets and select treatments for their refractory cancers. J Clin Oncol 28:4877-4883, 2010
24. Mick R, Crowley JJ, Carroll RJ: Phase II clinical trial design for noncytotoxic anticancer agents for which time to disease progression is the primary endpoint. Control Clin Trials 21:343-359, 2000 (Pubitemid 30456294)
25. Kravitz RL, Duan N, Niedzinski EJ, et al: What ever happened to N-of-1 trials? Insiders' perspectives and a look to the future. Milbank Q 86:533-555, 2008
26. Wegman AC, van der Windt DA, Stalman WA, et al: Conducting research in individual patients: Lessons learnt from two series of N-of-1 trials. BMC Fam Pract 7:54, 2006
27. Robertson JF, Steger GG, Neven P, et al: Activity of fulvestrant in HER2-overexpressing advanced breast cancer. Ann Oncol 21:1246-1253, 2010
28. Dufresne A, Pivot X, Tournigand C, et al: Impact of chemotherapy beyond the first line in patients with metastatic breast cancer. Breast Cancer Res Treat 107:275-279, 2008 (Pubitemid 350265698)
29. Capdevila J, Ramos FJ, Macarulla T, et al: The role of salvage treatment in advanced colorectal cancer. Crit Rev Oncol Hematol 71:53-61, 2009
30. Chang MH, Ahn JS, Lee J, et al: The efficacy of pemetrexed as a third- or fourth-line therapy and the significance of thymidylate synthase expression in patients with advanced non-small cell lung cancer. Lung Cancer 69:323-329, 2010
31. Horstmann E, McCabe MS, Grochow L, et al: Risks and benefits of phase 1 oncology trials, 1991 through 2002. N Engl J Med 352:895-904, 2005
32. Lee JK, Coutant C, Kim YC, et al: Prospective comparison of clinical and genomic multivariate predictors of response to neoadjuvant chemotherapy in breast cancer. Clin Cancer Res 16:711-718, 2010
33. Frei E III: Combination cancer therapy: Presidential address. Cancer Res 32:2593-2607, 1972